{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:10:00Z","timestamp":1791155400082,"version":"4.1.0"},"reference-count":215,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.biopha.2014.04.010","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T18:15:18Z","timestamp":1398708918000},"page":"665-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Drug\u2013drug interactions in HIV positive cancer patients"],"prefix":"10.1016","volume":"68","author":[{"given":"Brian Thabile","family":"Flepisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bouic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Sissolak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0005","doi-asserted-by":"crossref","first-page":"e65814","DOI":"10.1371\/journal.pone.0065814","article-title":"Extracting drug-drug interaction from the biomedical literature using a stacked generalization-based approach","volume":"8","author":"He","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.critrevonc.2005.03.007","article-title":"Drug-drug interactions in oncology: why are they important and can they be minimized?","volume":"55","author":"Blower","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","article-title":"Drug interactions in oncology","volume":"5","author":"Beijnen","year":"2004","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.biopha.2014.04.010_bib0020","first-page":"4741","article-title":"Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients","volume":"29","author":"Lemachatti","year":"2009","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0025","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug- drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.critrevonc.2008.10.013","article-title":"Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice","volume":"72","author":"Mounier","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00280-004-0998-4","article-title":"Potential for drug interactions in hospitalized cancer patients","volume":"56","author":"Riechelmann","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000086921","article-title":"Interactions of anti-infectives: a review","volume":"51","author":"Barcia","year":"2005","journal-title":"Chemotherapy"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/0022-3859.85207","article-title":"A study of drug-drug interactions in cancer patients of a south Indian tertiary care teaching hospital","volume":"57","author":"Kannan","year":"2011","journal-title":"J Postgrad Med"},{"issue":"12","key":"10.1016\/j.biopha.2014.04.010_bib0050","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","article-title":"Drug interactions in oncology: how common are they?","volume":"20","author":"Riechelmann","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.18773\/austprescr.2012.037","article-title":"Drug interactions: principles and practice","volume":"35","author":"Snyder","year":"2012","journal-title":"Aust Prescriber"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.mpaic.2010.12.008","article-title":"Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics","volume":"12","author":"Corrie","year":"2011","journal-title":"Anaesth Intensive Care Med"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2344\/0003-3006-58.1.31","article-title":"Adverse drug interactions","volume":"58","author":"Becker","year":"2011","journal-title":"Anesth Prog Spring"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0924-977X(01)00101-8","article-title":"Review of pharmacokinetic and pharmacodynamics interaction studies with citalopram","volume":"11","author":"Br\u00f8sen","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"issue":"33-34","key":"10.1016\/j.biopha.2014.04.010_bib0080","first-page":"546","article-title":"Drug interactions\u00a0\u2013\u00a0principles, examples and clinical consequences","volume":"109","author":"Cascorbi","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.biopha.2014.04.010_bib0085","series-title":"Drug interactions in Infectious Diseases","article-title":"Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion","author":"Kashuba","year":"2005"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1383\/anes.6.4.129.63634","article-title":"Pharmacodynamic and pharmacokinetic drug interactions","volume":"6","author":"Pleuvry","year":"2005","journal-title":"Anaesth Intensive Care Med"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc1629","article-title":"Pharmacokinetic variability of anticancer agents","volume":"5","author":"Undevia","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/00002512-200320100-00003","article-title":"Pharmacological factors influencing anticancer drug selection in the elderly","volume":"20","author":"John","year":"2003","journal-title":"Drugs Aging"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0105","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2217\/pgs.11.44","article-title":"Transporter-mediated drug-drug interactions","volume":"12","author":"M\u00fcller","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0110","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11481-006-9034-2","article-title":"MDR- and CYP3A4-mediated drug-drug interactions","volume":"1","author":"Pal","year":"2006","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pcl.2010.10.005","article-title":"Principles of pharmacology","volume":"58","author":"Feucht","year":"2011","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.biopha.2014.04.010_bib0125","series-title":"Enzyme Inhibition and Bioapplications","isbn-type":"print","doi-asserted-by":"crossref","DOI":"10.5772\/36711","article-title":"Cytochrome P450 Enzyme Inhibitors from Nature","author":"Badal","year":"2012","ISBN":"https:\/\/id.crossref.org\/isbn\/9789535105855"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003088-200342030-00002","article-title":"Drug interactions between antiretroviral drugs and comedicated agents","volume":"42","author":"de Maat","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"10.1016\/j.biopha.2014.04.010_bib0135","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJM200103293441307","article-title":"Interactions among drugs for HIV and opportunistic infections","volume":"344","author":"Piscitelli","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.biopha.2014.04.010_bib0140","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0300-483X(03)00247-6","article-title":"Cytochrome P450 enzyme polymorphisms and adverse drug reactions","volume":"192","author":"Pirmohamed","year":"2003","journal-title":"Toxicology"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0150","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update","volume":"30","author":"Spina","year":"2008","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0155","first-page":"17","article-title":"Interactions between antineoplastic agents and ARV drugs","volume":"21","author":"Edmunds-Ogbuokiri","year":"2009","journal-title":"HIV Clin"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bios.2012.05.043","article-title":"(CYP) enzymes and the development of CYP biosensors","volume":"39","author":"Schneider","year":"2013","journal-title":"Biosens Bioelectron"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/jpm2040175","article-title":"The making of a CYP3A biomarker panel for guiding drug therapy","volume":"2","author":"Wang","year":"2012","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0170","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.critrevonc.2003.04.004","article-title":"Understanding and preventing drug interactions in elderly patients","volume":"48","author":"Delafuente","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0175","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.trsl.2013.08.003","article-title":"Interaction of immunosuppressive drugs with human organic anion transporter (OAT)-1 and OAT3, and multidrug resistance-associated protein (MRP)-2 and MRP4","volume":"162","author":"El-Sheikh","year":"2013","journal-title":"Transl Res"},{"key":"10.1016\/j.biopha.2014.04.010_bib0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1191\/1078155203jp107oa","article-title":"A guide to clinically relevant drug interactions in oncology","volume":"9","author":"Lam","year":"2003","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0185","first-page":"1121","article-title":"HIV infection and cancer in the era of highly active antiretroviral therapy (Review)","volume":"17","author":"Barbaro","year":"2007","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0190","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/cid\/cit369","article-title":"Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy","volume":"57","author":"Yanik","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5112","key":"10.1016\/j.biopha.2014.04.010_bib0195","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1126\/science.8493571","article-title":"How does HIV cause AIDS?","volume":"260","author":"Weiss","year":"1993","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.biopha.2014.04.010_bib0200","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM200106073442306","article-title":"AIDS\u00a0\u2013\u00a0the first 20\u00a0years","volume":"344","author":"Sepkowitz","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0205","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00126334-200304150-00010","article-title":"Immune deficiency and risk for malignancy among persons with AIDS","volume":"32","author":"Mbulaiteye","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.biopha.2014.04.010_bib0210","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/jnci\/djm010","article-title":"HIV\/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS","volume":"99","author":"Biggar","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0215","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/jac\/dkq096","article-title":"Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1","volume":"65","author":"Taiwo","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0220","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32835dc068","article-title":"High cancer-related mortality in an urban, predominantly African-American, HIV-infected population","volume":"27","author":"Riedel","year":"2013","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0225","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/ijc.24741","article-title":"Cancer and viral infections in immunocompromised individuals","volume":"125","author":"Schulz","year":"2009","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2014.04.010_bib0230","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/cid\/cit497","article-title":"Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort","volume":"57","author":"Hleyhel","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eimc.2013.04.001","article-title":"Risk of cancers in HIV infection","volume":"31","author":"Costagliola","year":"2013","journal-title":"Enferm Infect Microbiol Clin"},{"issue":"9581","key":"10.1016\/j.biopha.2014.04.010_bib0240","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.biopha.2014.04.010_bib0245","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0250","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QAD.0b013e3282f47082","article-title":"Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals","volume":"22","author":"Long","year":"2008","journal-title":"AIDS"},{"issue":"14","key":"10.1016\/j.biopha.2014.04.010_bib0255","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.2011.396","article-title":"Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980\u20132007","volume":"305","author":"Shiels","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0260","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0959-8049(01)00120-4","article-title":"Epidemiology of AIDS-related tumours in developed and developing countries","volume":"37","author":"Dal Maso","year":"2001","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0265","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ctrv.2006.06.001","article-title":"Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives","volume":"32","author":"Vanni","year":"2006","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"10.1016\/j.biopha.2014.04.010_bib0270","first-page":"2354","article-title":"Kaposi\u2019 s sarcoma in HIV-positive patients: the state of art in the HAART era","volume":"17","author":"La Ferla","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0275","first-page":"1","article-title":"Kaposi sarcoma is the most common cancer diagnosed in HIV-infected persons","volume":"21","author":"Henderson","year":"2009","journal-title":"HIV Clin"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0280","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0190-9622(81)80010-2","article-title":"Disseminated Kaposi's sarcoma syndrome in young homosexual men","volume":"5","author":"Friedman-Kien","year":"1981","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0285","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0190-9622(93)70057-Z","article-title":"Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy","volume":"28","author":"Tappero","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0290","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0959-8049(01)00109-5","article-title":"Clinical aspects and management of AIDS-related Kaposi's sarcoma","volume":"37","author":"Levine","year":"2001","journal-title":"Eur J Cancer"},{"issue":"11-12","key":"10.1016\/j.biopha.2014.04.010_bib0295","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.cr.7290372","article-title":"AIDS and associated malignancies","volume":"15","author":"Wood","year":"2005","journal-title":"Cell Res"},{"key":"10.1016\/j.biopha.2014.04.010_bib0300","doi-asserted-by":"crossref","first-page":"485943","DOI":"10.1155\/2012\/485943","article-title":"AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy","volume":"2012","author":"Vishnu","year":"2012","journal-title":"Adv Hematol"},{"issue":"8745","key":"10.1016\/j.biopha.2014.04.010_bib0305","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0140-6736(91)92513-2","article-title":"AIDS-associated non-Hodgkin lymphoma","volume":"337","author":"Beral","year":"1991","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0310","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.0.CO;2-X","article-title":"Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS\/Cancer Study Group","volume":"73","author":"Cot\u00e9","year":"1997","journal-title":"Int J Cancer"},{"issue":"9844","key":"10.1016\/j.biopha.2014.04.010_bib0315","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0320","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V96.8.2730","article-title":"Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy","volume":"96","author":"Matthews","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.soncn.2006.01.004","article-title":"AIDS-related lymphoma","volume":"22","author":"Levine","year":"2006","journal-title":"Semin Oncol Nurs"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0330","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/sti.76.5.335","article-title":"AIDS related systemic non-Hodgkin's lymphoma","volume":"76","author":"Powles","year":"2000","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.biopha.2014.04.010_bib0335","series-title":"Initial treatment of advanced stage (III\/IV) follicular lymphoma. UpToDate","author":"Freedman","year":"2013"},{"key":"10.1016\/j.biopha.2014.04.010_bib0340","series-title":"British HIV Association guidelines for HIV associated malignancies. Consultation Draft 2013","author":"Bower","year":"2013"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0345","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.semcancer.2013.08.004","article-title":"Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology","volume":"23","author":"Gloghini","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"19","key":"10.1016\/j.biopha.2014.04.010_bib0350","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1200\/JCO.2005.11.973","article-title":"AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy","volume":"23","author":"Lim","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0355","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/hiv.10.54","article-title":"HIV-related Lymphoma","volume":"4","author":"Lee","year":"2010","journal-title":"HIV Ther"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0360","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.transci.2011.01.007","article-title":"Impact of the HIV epidemic and anti-retroviral treatment policy on lymphoma incidence and subtypes seen in the Western Cape of South Africa, 2002\u20132009: preliminary findings of the Tygerberg Lymphoma Study Group","volume":"44","author":"Abayomi","year":"2011","journal-title":"Transfus Apher Sci"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0365","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","article-title":"Non-Hodgkin lymphoma: an update","volume":"5","author":"Hennessy","year":"2004","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2014.04.010_bib0370","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/modpathol.2012.178","article-title":"Aggressive B-cell lymphomas: how many categories do we need?","volume":"26","author":"Said","year":"2013","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0375","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.mpmed.2009.01.009","article-title":"Aggressive non-Hodgkin's lymphoma","volume":"37","author":"Lowry Lisa","year":"2008","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0380","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2011.08877.x","article-title":"Burkitt lymphoma in adults","volume":"156","author":"Linch","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0385","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejogrb.2004.11.024","article-title":"Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions?","volume":"121","author":"Agorastos","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0390","first-page":"5","article-title":"Management of cervical cancer","volume":"20","author":"Hughes","year":"2011","journal-title":"Eur J Cancer Care"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0395","first-page":"15","article-title":"Evaluation of Ki67, p16 and CK17 markers in differentiating cervical intraepithelial neoplasia and benign lesions","volume":"38","author":"Sari Aslani","year":"2013","journal-title":"Iran J Med Sci"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0400","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1066896913496147","article-title":"Role of p16, CK17, p63, and human papillomavirus in Diagnosis of cervical intraepithelial neoplasia and distinction from its mimics","volume":"22","author":"Selvi","year":"2013","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.biopha.2014.04.010_bib0405","series-title":"Prognostic factors for squamous cell cervical cancer: Tumor markers, hormones, smoking, and S-phase fraction","author":"Lindstr\u00f6m","year":"2010"},{"key":"10.1016\/j.biopha.2014.04.010_bib0410","series-title":"Invasive cervical cancer: epidemiology, risk factors, clinical manifestations, and diagnosis. UpToDate","author":"Frumovitz","year":"2013"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0415","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bpobgyn.2004.10.002","article-title":"HIV and cancer of the cervix","volume":"19","author":"Chirenje","year":"2005","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0420","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/IGC.0b013e3182094d78","article-title":"Age at diagnosis of preinvasive and invasive cervical neoplasia in South Africa: HIV-positive versus HIV-negative women","volume":"21","author":"van Bogaert","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0425","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/157016210793499240","article-title":"The impact of HAART on HPV-related cervical disease","volume":"8","author":"Adler","year":"2010","journal-title":"Curr HIV Res"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0430","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mdh281","article-title":"HIV-related non-Hodgkin's lymphoma (HIV-NHL) in the era of highly active antiretroviral therapy (HAART): some still unanswered questions for clinical management","volume":"15","author":"Spina","year":"2004","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.biopha.2014.04.010_bib0435","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199706053362304","article-title":"Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group","volume":"336","author":"Kaplan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2014.04.010_bib0440","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4137\/CMO.S5028","article-title":"CD4 count and anti retroviral therapy for HIV positive patients with cancer in nigeria\u00a0\u2013\u00a0a pilot study","volume":"4","author":"Ntekim","year":"2010","journal-title":"Clin Med Insights Oncol"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0445","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/pharmaceutics3040745","article-title":"Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management","volume":"3","author":"Rathbun","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2014.04.010_bib0450","series-title":"HIV\/AIDS","author":"National institute of allergy infectious diseases (NIH)","year":"2013"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0455","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11318110-000000000-00000","article-title":"Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action","volume":"49","author":"Bazzoli","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.biopha.2014.04.010_bib0460","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.biopha.2014.04.010_bib0465","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1742-6405-7-18","article-title":"Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings","volume":"7","author":"Ramautarsing","year":"2010","journal-title":"AIDS Res Ther"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0470","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/381678","article-title":"The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities","volume":"38","author":"Anderson","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0475","doi-asserted-by":"crossref","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0480","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/apc.2012.0169","article-title":"Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review","volume":"26","author":"van Maarseveen","year":"2012","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0485","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.aids.0000162333.35686.4c","article-title":"Renal tubular transporters and antiviral drugs: an update","volume":"19","author":"Izzedine","year":"2005","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0490","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s15010-012-0308-8","article-title":"Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients","volume":"41","author":"Jung","year":"2013","journal-title":"Infection"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0495","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1124\/dmd.108.020826","article-title":"Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection","volume":"36","author":"Jung","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.biopha.2014.04.010_bib0500","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/138161206776055840","article-title":"Current HIV treatment guidelines\u00a0\u2013\u00a0an overview","volume":"12","author":"Rathbun","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"9417","key":"10.1016\/j.biopha.2014.04.010_bib0505","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.biopha.2014.04.010_bib0510","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00126334-200202011-00003","article-title":"Pharmacokinetic enhancement of protease inhibitors","volume":"29","author":"Acosta","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0515","doi-asserted-by":"crossref","first-page":"e54349","DOI":"10.1371\/journal.pone.0054349","article-title":"Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages","volume":"8","author":"Zha","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0520","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/bdd.1832","article-title":"Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs","volume":"34","author":"Liu","year":"2013","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0525","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jnr.21898","article-title":"Upregulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line","volume":"87","author":"Zastre","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.biopha.2014.04.010_bib0530","series-title":"Definition of Highly Active Antiretroviral Therapy (HAART): While this term is quickly becoming anachronistic we maintain use of this term for use of combination antiretroviral therapy to distinguish it from truly \u201csuboptimal\u201d monotherapy or combinations","year":"2009"},{"issue":"17","key":"10.1016\/j.biopha.2014.04.010_bib0535","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archinternmed.2012.3216","article-title":"Choice of Initial combination antiretroviral therapy in individuals with HIV infection: determinants and outcomes","volume":"172","author":"Elzi","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.biopha.2014.04.010_bib0540","series-title":"AIDS-related Kaposi sarcoma: Staging and treatment. UpToDate","author":"Groopman","year":"2012"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0545","first-page":"236","article-title":"Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment","volume":"14","author":"Dezube","year":"2004","journal-title":"AIDS Read"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0550","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(07)70036-0","article-title":"Management of AIDS-related Kaposi's sarcoma","volume":"8","author":"Di Lorenzo","year":"2007","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0555","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5858\/arpa.2012-0101-RS","article-title":"Kaposi sarcoma","volume":"137","author":"Radu","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0560","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.critrevonc.2004.10.009","article-title":"Treatments of AIDS-related Kaposi's sarcoma","volume":"53","author":"Aversa","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0565","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1634\/theoncologist.10-6-412","article-title":"AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy","volume":"10","author":"Cheung","year":"2005","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0570","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1023\/A:1008359628245","article-title":"Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma","volume":"9","author":"Tavio","year":"1998","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0575","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","article-title":"Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma","volume":"12","author":"Lebb\u00e9","year":"1998","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0580","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nm0302-225","article-title":"HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma","volume":"8","author":"Sgadari","year":"2002","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0585","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc797","article-title":"AIDS-related malignancies","volume":"2","author":"Boshoff","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0590","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/jac\/dkg199","article-title":"How does HAART lead to the resolution of Kaposi's sarcoma?","volume":"51","author":"Stebbing","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0595","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1468-1293.2008.00608.x","article-title":"British HIV association guidelines for HIV-associated malignancies 2008","volume":"9","author":"Bower","year":"2008","journal-title":"HIV Med"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0600","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-3156.2005.01491.x","article-title":"AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa","volume":"10","author":"Sissolak","year":"2005","journal-title":"Trop Med Int Health"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0605","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","article-title":"Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma","volume":"17","author":"Gill","year":"1999","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0610","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.10634","article-title":"Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma","volume":"95","author":"Tulpule","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2014.04.010_bib0615","series-title":"AIDS associated malignancies","first-page":"221","author":"Bower","year":"2006"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0620","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4065\/80.8.1087","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","volume":"80","author":"Ansell","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.biopha.2014.04.010_bib0625","series-title":"AIDS-related lymphomas: Treatment of systemic lymphoma. UpToDate","author":"Kaplan","year":"2014"},{"key":"10.1016\/j.biopha.2014.04.010_bib0630","series-title":"Fighting blood cancers. Facts","author":"Leukemia","year":"2013"},{"key":"10.1016\/j.biopha.2014.04.010_bib0635","series-title":"Overview of care for adult survivors of non-Hodgkin lymphoma. UpToDate","author":"Davuds","year":"2013"},{"issue":"11","key":"10.1016\/j.biopha.2014.04.010_bib0640","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00277-013-1811-4","article-title":"Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews","volume":"92","author":"Lindenmeyer","year":"2013","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0645","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2005-09-3600","article-title":"AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy","volume":"107","author":"Mounier","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2014.04.010_bib0650","series-title":"HIV-Associated Malignancies. HIV Curriculum","author":"Mehta","year":"2009"},{"issue":"19","key":"10.1016\/j.biopha.2014.04.010_bib0655","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0660","first-page":"704","article-title":"The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy","volume":"90","author":"Navarro","year":"2005","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.biopha.2014.04.010_bib0665","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1080\/10428190600658688","article-title":"Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS","volume":"47","author":"Diamond","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0670","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cncr.21759","volume":"106","author":"Weiss","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0675","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ajh.23420","article-title":"Treatments for non-Hodgkin lymphoma in HIV-positive patients: quantifying incremental benefit from 1993 to 2004 by meta-regression","volume":"88","author":"Messori","year":"2013","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.biopha.2014.04.010_bib0680","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I treat HIV-associated lymphoma","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0685","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/CCO.0b013e32833ed848","article-title":"Front-line management of diffuse large B cell lymphoma","volume":"22","author":"Cabanillas","year":"2010","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0690","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.biopha.2014.04.010_bib0695","series-title":"Initial treatment of advanced stage diffuse large B cell lymphoma. UpToDate","author":"Freedman","year":"2013"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0700","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/QAI.0b013e3182a03e9b","article-title":"Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa","volume":"64","author":"de Witt","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0705","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/QAD.0000000000000133","article-title":"HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era","volume":"28","author":"Coutinho","year":"2013","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0710","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0715","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.biopha.2014.04.010_bib0720","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0725","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.biopha.2014.04.010_bib0730","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.biopha.2014.04.010_bib0735","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma","volume":"24","author":"Bou\u00e9","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.biopha.2014.04.010_bib0740","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.22275","article-title":"Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies","volume":"87","author":"Castillo","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0745","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0268-960X(91)90040-J","article-title":"Management of pediatric non-Hodgkin's lymphoma","volume":"5","author":"Blay","year":"1991","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0750","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1368-8375(97)00041-9","article-title":"Burkitt's lymphoma","volume":"34","author":"Shapira","year":"1998","journal-title":"Oral Oncol"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0755","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3109\/07357900009012197","article-title":"Burkitt's lymphoma: molecular pathogenesis and treatment","volume":"18","author":"Bishop","year":"2000","journal-title":"Cancer Invest"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0760","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdh262","article-title":"Treatment of Burkitt's\/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens","volume":"15","author":"Smeland","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2014.04.010_bib0765","series-title":"Treatment of Burkitt leukemia\/lymphoma in adults. UpToDate","author":"Freedman","year":"2013"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.biopha.2014.04.010_bib0770","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3816\/CLM.2002.s.011","article-title":"Challenges in the management of Burkitt's lymphoma","volume":"3","author":"Levine","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0775","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.biopha.2014.04.010_bib0780","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","article-title":"Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group","volume":"24","author":"W\u00e4sterlid","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0785","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2014.04.010_bib0790","doi-asserted-by":"crossref","first-page":"735392","DOI":"10.1155\/2012\/735392","article-title":"HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M\/IVAC with or without rituximab in the HAART era","volume":"2012","author":"Rodrigo","year":"2012","journal-title":"Adv Hematol"},{"issue":"12","key":"10.1016\/j.biopha.2014.04.010_bib0795","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S0025-6196(11)61104-X","article-title":"Prevention, diagnosis, and treatment of cervical cancer","volume":"82","author":"Long","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"7623","key":"10.1016\/j.biopha.2014.04.010_bib0800","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/bmj.39337.615197.80","article-title":"Diagnosis and management of cervical cancer","volume":"335","author":"Petignat","year":"2007","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0805","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.semradonc.2009.11.006","article-title":"Adaptive management of cervical cancer radiotherapy","volume":"20","author":"Tanderup","year":"2010","journal-title":"Semin Radiat Oncol"},{"issue":"9284","key":"10.1016\/j.biopha.2014.04.010_bib0810","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(01)05965-7","article-title":"Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis","volume":"358","author":"Green","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0815","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/CCO.0b013e32833cff4f","article-title":"Issues in cervical cancer incidence and treatment in HIV","volume":"22","author":"Einstein","year":"2010","journal-title":"Curr Opin Oncol"},{"issue":"21","key":"10.1016\/j.biopha.2014.04.010_bib0820","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2005.10.522","article-title":"Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Monk","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0825","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/11534370-000000000-00000","article-title":"Pharmacotherapy options for locally advanced and advanced cervical cancer","volume":"70","author":"Due\u00f1as-Gonz\u00e1lez","year":"2010","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.biopha.2014.04.010_bib0830","first-page":"123","article-title":"Chemotherapy for stage IVB or recurrent cancer of the uterine cervix","author":"Omura","year":"1996","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"15","key":"10.1016\/j.biopha.2014.04.010_bib0835","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.biopha.2014.04.010_bib0840","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.biopha.2014.04.010_bib0845","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","article-title":"Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N Engl J Med"},{"issue":"3 Pt 2","key":"10.1016\/j.biopha.2014.04.010_bib0850","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0090-8258(03)00465-7","article-title":"The role of topotecan in the treatment of advanced cervical cancer","volume":"90","author":"Fiorica","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2014.04.010_bib0855","series-title":"Management of locally advanced cervical cancer. UpToDate","author":"De Los Santos","year":"2014"},{"issue":"10\u00a0Suppl.","key":"10.1016\/j.biopha.2014.04.010_bib0860","doi-asserted-by":"crossref","first-page":"211s","DOI":"10.1200\/JCO.2003.01.222","article-title":"Combined-modality therapy of locally advanced cervical cancer","volume":"21","author":"Rose","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0865","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0360-3016(87)90076-9","article-title":"Effect of cisplatin resistance on cellular radiation response","volume":"13","author":"Wallner","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0870","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00001813-200011000-00008","article-title":"Anti- neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-tumor chemosensitivity assay","volume":"11","author":"Boabang","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2014.04.010_bib0875","series-title":"Management of cervical cancer: a national guideline","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2008"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0880","doi-asserted-by":"crossref","first-page":"17382","DOI":"10.7448\/IAS.15.2.17382","article-title":"Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa","volume":"15","author":"Firnhaber","year":"2012","journal-title":"J Int AIDS Soc"},{"issue":"13","key":"10.1016\/j.biopha.2014.04.010_bib0885","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/QAD.0b013e32835536a3","article-title":"Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART","volume":"26","author":"Adler","year":"2012","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0890","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200544020-00001","article-title":"Interactions between antiretrovirals and antineoplastic drug therapy","volume":"44","author":"Antoniou","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0895","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/QAD.0000000000000071","article-title":"Malignancies in HIV\/AIDS: from epidemiology to therapeutic challenges","volume":"28","author":"Rubinstein","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0900","first-page":"19","article-title":"The use of antiretroviral therapy in patients undergoing treatment for HIV-related neoplastic disease","volume":"9","author":"Little","year":"2003","journal-title":"Res Initiat Treat Action"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib0905","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-3565(24)39081-0","article-title":"Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance","volume":"294","author":"Yao","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopha.2014.04.010_bib0910","first-page":"25","article-title":"Potential interactions between antineoplastics and antiretrovirals. Pharm D","author":"Antoniou","year":"2013","journal-title":"FCSHP"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0915","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00280-010-1509-4","article-title":"Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial","volume":"68","author":"Cianfrocca","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0920","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/ijc.27912","article-title":"P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel","volume":"132","author":"Hendrikx","year":"2013","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib0925","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s002800050932","article-title":"Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma\u00a0\u2013\u00a0drug\u2013drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study","volume":"43","author":"Nannan Panday","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib0930","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bcp.2007.01.027","article-title":"Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein","volume":"73","author":"Storch","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.biopha.2014.04.010_bib0935","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/qjmed\/hcl115","article-title":"AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy","volume":"99","author":"Palmieri","year":"2006","journal-title":"QJM"},{"issue":"12","key":"10.1016\/j.biopha.2014.04.010_bib0940","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/annonc\/mdh464","article-title":"Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma","volume":"15","author":"Toffoli","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.biopha.2014.04.010_bib0945","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/jac\/dki050","article-title":"Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients","volume":"55","author":"Cruciani","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0950","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkq448","article-title":"Emerging antiretroviral drug interactions","volume":"66","author":"Pham","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.biopha.2014.04.010_bib0955","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2004-05-1747","article-title":"Protease inhibitors potentiate chemotherapy-induced neutropenia","volume":"104","author":"Bower","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib0960","first-page":"104","article-title":"Modulation of P-glycoprotein mediated multidrug resistance (MDR) in cancer using chemosensitizers","volume":"1","author":"Velingkar","year":"2010","journal-title":"IJPSR"},{"issue":"23","key":"10.1016\/j.biopha.2014.04.010_bib0965","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes","volume":"53","author":"Chang","year":"1993","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0970","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","article-title":"Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide","volume":"59","author":"Huang","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"22","key":"10.1016\/j.biopha.2014.04.010_bib0975","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/jnci\/84.22.1744","article-title":"Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide","volume":"84","author":"Boddy","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.biopha.2014.04.010_bib0980","series-title":"Antiretroviral-Chemotherapy Interactions: CHOP Regimen","author":"Wong","year":"2013"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib0985","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1310\/700B-9QT3-HGN9-Q3FQ","article-title":"Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy","volume":"2","author":"N\u00fa\u00f1ez","year":"2001","journal-title":"HIV Clin Trials"},{"issue":"8","key":"10.1016\/j.biopha.2014.04.010_bib0990","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2001.19.8.2171","article-title":"Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy","volume":"19","author":"Ratner","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2014.04.010_bib0995","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2867-5-30","article-title":"ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal","volume":"5","author":"Choi","year":"2005","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib1000","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14622416.9.1.105","article-title":"ABC multidrug transporters: structure, function and role in chemoresistance","volume":"9","author":"Sharom","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.biopha.2014.04.010_bib1005","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0090-9556(24)15196-3","article-title":"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes","volume":"28","author":"Kajita","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib1010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QAI.0b013e31817bebeb","article-title":"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals","volume":"48","author":"Busse","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2014.04.010_bib1015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/mco.2013.202","article-title":"A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress","volume":"2","author":"Xu","year":"2013","journal-title":"Mol Clin Oncol"},{"issue":"9","key":"10.1016\/j.biopha.2014.04.010_bib1020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.biopha.2014.04.010_bib1025","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.biopha.2014.04.010_bib1030","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects","volume":"3","author":"Florea","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2014.04.010_bib1035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/CCO.0b013e32832f3e04","article-title":"Targeted therapies to treat non-AIDS defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook","volume":"21","author":"Deeken","year":"2009","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib1040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: a review","volume":"334","author":"Yao","year":"2007","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.biopha.2014.04.010_bib1045","first-page":"562790","article-title":"Nephrotoxicity of HAART","volume":"2011","author":"Kalyesubula","year":"2011","journal-title":"AIDS Res Treat"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib1050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.106.110346","article-title":"Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)","volume":"319","author":"Yonezawa","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.biopha.2014.04.010_bib1055","first-page":"4183","article-title":"Saving ears and kidneys from cisplatin","volume":"33","author":"Wensing","year":"2013","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.biopha.2014.04.010_bib1060","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bcp.2005.09.020","article-title":"Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat","volume":"70","author":"Yonezawa","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.biopha.2014.04.010_bib1065","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","article-title":"Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2","volume":"167","author":"Ciarimboli","year":"2005","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.biopha.2014.04.010_bib1070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/era.11.201","article-title":"Molecular mechanisms of cisplatin resistance in bladder cancer","volume":"12","author":"Drayton","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.biopha.2014.04.010_bib1075","series-title":"Systemic therapy for malignancy in patients on anti retroviral medications. UpToDate","author":"Rudek","year":"2012"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332214000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332214000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:55:28Z","timestamp":1760093728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332214000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":215,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0753332214000584"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2014.04.010","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug\u2013drug interactions in HIV positive cancer patients","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2014.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}